Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Afatinib (Primary) ; Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.